Conversely, inhibiting YAP1, after the acute phase of AKI, attenuated renal function decline and interstitial fibrosis, further suggesting that the sustained activation of YAP1 in the post-acute phase of AKI is involved in CKD progression [93,94]. The gene discussed is YAP1; the disease is acute kidney injury.